20 (AIDX) Convertible Debt (2025 - 2026)
20 (AIDX) posted Convertible Debt of $570000.0 for Q1 2026, down 7.97% on a QoQ basis from $619355.0 in Q4 2025.
20 (AIDX) Convertible Debt (2025 - 2026) Analysis & Trends
20's Convertible Debt history runs 2 years deep, the most recent figure standing at $570000.0 for Q1 2026.
- Quarterly Convertible Debt changed N/A year-over-year to $570000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $570000.0 (changed N/A YoY) and the FY2025 annual result came in at $619355.0, changed N/A from the prior year.
- Convertible Debt was $570000.0 for Q1 2026 at 20, down from $619355.0 in the prior quarter.
- Across five years, Convertible Debt topped out at $619355.0 in Q4 2025 and bottomed at $570000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | 20 | 3.91 Mn | -313,912.28 | 62,884.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 570,000.00 |
| Dec 31, 2025 | 619,355.00 |